MYRF Gene Mutation: Clinical Manifestations and Management
Pathogenic MYRF (myelin regulatory factor) gene mutations cause a multisystem syndrome characterized by congenital heart defects, genitourinary anomalies, congenital diaphragmatic hernia, and pulmonary hypoplasia—collectively termed MYRF-related cardiac-urogenital syndrome (MYRF-CUGS). 1, 2
Clinical Manifestations
Cardiac Abnormalities (76% of cases)
- Congenital heart defects including hypoplastic left heart syndrome, scimitar syndrome, septal defects (atrial and ventricular), and valvular anomalies 1, 2
- These cardiac lesions represent the most common and life-threatening manifestations 2
Genitourinary Anomalies (50-70% of cases)
- In 46,XY individuals: ambiguous genitalia, hypospadias, cryptorchidism, underdeveloped testicular tissue, inadequate masculinization, and persistent Müllerian ducts 1, 3
- In 46,XX individuals: absent uterus, vagina, and ovaries; renal malformations including kidney duplication 4
- Testicular dysgenesis can occur as an isolated finding or with severe cardiopulmonary issues 3
Respiratory and Diaphragmatic Defects (59% of cases)
- Congenital diaphragmatic hernia is a cardinal feature 1, 2, 5
- Pulmonary hypoplasia and pulmonary artery hypoplasia 1
Neurological and Developmental Features
- Developmental delay and intellectual disability in survivors of the neonatal period 1
- Primary angle closure glaucoma and high hyperopia have been associated with MYRF truncation mutations 6
Other Manifestations
Recommended Screening at Diagnosis
Immediate Neonatal/Pediatric Evaluation
- Comprehensive echocardiogram and electrocardiogram to assess for structural heart defects and arrhythmias 1, 2
- Detailed genitourinary examination including assessment of external genitalia, palpation for gonads, and evaluation for ambiguous genitalia 3
- Pelvic/abdominal ultrasound to identify internal reproductive structures and renal anomalies 4
- Chest radiography to evaluate for congenital diaphragmatic hernia and pulmonary hypoplasia 2
- Karyotype analysis in all cases with genital ambiguity or disorders of sex development 3, 4
Hormonal Assessment (for DSD cases)
- Testosterone, anti-Müllerian hormone (AMH), luteinizing hormone (LH), follicle-stimulating hormone (FSH) 3
- Additional endocrine evaluation as clinically indicated 3
Neurological Baseline
- Developmental assessment and neurological examination 1
- Ophthalmologic evaluation including assessment for hyperopia and glaucoma risk 6
Genetic Evaluation
- Genetic counseling for the proband and family regarding autosomal dominant inheritance with variable expressivity 2
- Cascade genetic testing of first-degree relatives for the identified pathogenic variant 2, 3
Management Recommendations
Cardiac Management
- Immediate cardiology consultation for all patients with identified heart defects 2
- Surgical intervention timing depends on specific cardiac lesion severity and hemodynamic stability 2
- Long-term cardiology follow-up for all patients, even those without initial cardiac findings, given potential for late manifestations 2
Genitourinary Management
- Multidisciplinary DSD team evaluation including pediatric endocrinology, urology, and genetics 3
- Gender assignment decisions should involve comprehensive discussion with family, considering gonadal function, surgical options, and long-term outcomes 3
- Gonadectomy considerations for dysgenetic gonads in 46,XY individuals due to malignancy risk 3
- Hormone replacement therapy as appropriate for age and gender identity 3
Surgical Interventions
- Congenital diaphragmatic hernia repair as clinically indicated, often requiring neonatal intensive care 2, 5
- Cardiac surgical procedures based on specific defects identified 2
- Genitoplasty procedures individualized based on anatomy and family preferences 3
Developmental and Neurological Monitoring
- Regular developmental assessments starting in infancy for early intervention services 1
- Annual ophthalmologic examinations to monitor for glaucoma development, particularly in adolescence and adulthood 6
- Intraocular pressure monitoring in patients with hyperopia 6
Family Screening and Genetic Counseling
- Mutation-specific genetic testing of first-degree relatives is essential given autosomal dominant inheritance 2, 3
- Pretest genetic counseling to discuss variable expressivity and significant intrafamilial phenotypic variability 2
- Prenatal diagnosis options should be discussed for future pregnancies, given the severe congenital anomalies and poor prognosis in some cases 2
Critical Pitfalls to Avoid
Do not assume isolated findings exclude MYRF-CUGS: The syndrome exhibits marked variable expressivity, with some patients presenting with isolated testicular dysgenesis without cardiac or pulmonary involvement, while others have severe multisystem disease 3, 4. Even subtle phenotypes warrant comprehensive evaluation 4.
Do not delay cardiac evaluation: Cardiac defects are the most life-threatening manifestation and require immediate assessment even in the absence of obvious symptoms 2.
Recognize PAGOD syndrome overlap: Individuals with the clinical diagnosis of PAGOD syndrome (pulmonary artery and lung hypoplasia, agonadism, omphalocele, and diaphragmatic defects) should be screened for MYRF pathogenic variants 1.
Anticipate poor prenatal prognosis: Prenatally diagnosed cases often have more severe manifestations than postnatally identified cases, with congenital anomalies carrying significant morbidity and mortality 2.